immunity News and Research

RSS

Memory B cells indicate durable immunity in COVID-19

Now a new study by researchers at SUNY Upstate Medical University and published recently on the preprint server medRxiv in September 2020 shows that memory B cells are upregulated in convalescent COVID-19 patients, correlating with a better immune response and shorter symptom duration.

8 Sep 2020

The T cell responses in COVID-19 recovered individuals

A recent study demonstrates that functional CD4+ and CD8+ T cells specifically targeting the entire proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain active in individuals who have recovered from severe or mild coronavirus disease 2019 (COVID-19). Moreover, the magnitude of T cell response is correlated with the antibody response. The study is published in the journal Nature Immunology.

8 Sep 2020

Blanket approach to prescribing medication during pregnancy may put low birth weight babies at risk

New research led by the University of South Australia shows that a blanket approach to prescribing medication during pregnancy may put low birth weight babies at risk for the rest of their lives.

8 Sep 2020

Limited gut inflammation in COVID-19

A new study by researchers at the Icahn School of Medicine at Mount Sinai and published on the preprint server medRxiv in September 2020 shows that gut infection with this virus produces primarily mucosal immunity but also a limited inflammatory response.

8 Sep 2020

Study finds strong T cell responses in patients recovered from COVID-19

Oxford University researchers have found that natural infection with COVID-19 produces a robust T cell response, including inducing T cell ‘memory’ to potentially fight future infections.

8 Sep 2020

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

A recent study published in the preprint server medRxiv in September 2020 shows that the already approved drug families called P13K/mTOR and topoisomerase inhibitors may be useful in reducing individual susceptibility to the virus.

7 Sep 2020

Novel RNA vaccine from Arcturus Therapeutics protects mice against SARS-CoV-2

A new study published on the preprint server bioRxiv in September 2020 reports a novel RNA vaccine platform that shows robust protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice and performs much better than a conventional mRNA vaccine. This could allow single-dose immunization, allowing progress towards global vaccination.

6 Sep 2020

Seasonal influenza and COVID-19 risk

In a new study published on the preprint server medRxiv, researchers from Laval University and McGill University in Canada reviewed evidence from 18 relevant studies on a possible interaction between influenza vaccines on non-influenza respiratory disease (NIRD).

6 Sep 2020

Antibody responses against seasonal common cold coronaviruses may protect against SARS-CoV-2

With the use of an accurate high throughput assay, researchers from the Weizmann Institute of Science and Magen David Adom Blood Services in Israel showed substantial inter-individual variability and antibody cross-reactivity against seasonal coronaviruses upon SARS-CoV-2 infection, with important implications for immune surveys and vaccines. The study is currently available on the medRxiv* preprint server.

6 Sep 2020

Transparent Government builds trust and successful COVID-19 containment

The combined impact of the pandemic and these non-pharmaceutical interventions (NPIs) has taken a heavy toll on society, and this has led to much discussion as to the relative merits of these measures. A recent study published on the preprint server medRxiv in September 2020 shows that public trust is vital for the success of any such intervention.

6 Sep 2020

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.

5 Sep 2020

Spike-based priming leads to high neutralizing activity in animal models

A new report by researchers at the University of Melbourne and published on the preprint server bioRxiv in September 2020 reports on the use of a two-protein two-dose vaccine regimen and its immunogenicity in two animal models.

4 Sep 2020

CRISPR-based system suppresses genes related to AAV antibody production

Gene therapy generally relies on viruses, such as adeno-associated virus (AAV), to deliver genes into a cell. In the case of CRISPR-based gene therapies, molecular scissors can then snip out a defective gene, add in a missing sequence or enact a temporary change in its expression, but the body's immune response to AAV can thwart the whole endeavor.

4 Sep 2020

Research compares T cell responses to SARS-CoV-2 and influenza

As the COVID-19 pandemic continues to grow, scientists are focusing on understanding how the host immune system responds to the virus in order to better shape public health responses and develop effective vaccines. A new study published on the preprint server medRxiv in September 2020 reports the T cell memory response to the SARS-CoV-2 spike protein, recombinant nucleocapsid protein, and other pooled peptides derived from convalescent patients.

3 Sep 2020

UChicago Medicine launches clinical trial to test the potential of antibody against SARS-CoV-2

The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.

3 Sep 2020

Study: Antibiotics have prolonged effects on breast milk microbiota in mothers of preterm infants

A team led by researchers at the University of Toronto and The Hospital for Sick Children has found that mothers of preterm babies have highly individual breast milk microbiomes, and that even short courses of antibiotics have prolonged effects on the diversity and abundance of microbes in their milk.

3 Sep 2020

Dozens of U.S. hospitals poised to defy FDA’s directive on COVID plasma

Dozens of major hospitals across the U.S. are grappling with whether to ignore a federal decision allowing broader emergency use of blood plasma from recovered COVID patients to treat the disease in favor of dedicating their resources to a gold-standard clinical trial that could help settle the science for good.

3 Sep 2020

COVID-19 virus and antibodies can coexist in young patients, shows study

With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

3 Sep 2020

Antibody responses in recovered COVID-19 individuals from India

India has been hit hard by COVID-19, with at least 66,000 deaths and almost 4 million cases. The need to understand the infection, including the various antibody isotypes, and whether neutralizing antibodies and memory B cells are being produced, has driven much research into the way immunity is developing in Indian patients.

3 Sep 2020

A global study to determine COVID-19 health and psychosocial consequences

The current paper lays out the details of a longitudinal study that aims to follow up COVID-19 patients, including any pre-existing chronic illnesses as well as the medical care they received during their illness. A significant minority of convalescents appears to have prolonged disease sequelae.

3 Sep 2020